MedTrace Logo

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-10-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.

Conditions

Interventions

DRUG

Niraparib

Eligible participants will receive daily dosing of Niraparib.

Sponsors & Collaborators

Principal Investigators

  • Virginia Rhodes · Tempus AI, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2024-08-06
Completion
2024-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169437 on ClinicalTrials.gov